Mark Stanley Berger - 01 Sep 2021 Form 4 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Reporting relationship: Chief Medical Officer
Issuer ticker: ATNM
Reported as of: 01 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2021, 17:04:11 UTC
Next SEC filing: 28 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Mark Berger

Key filing fact

Mark Stanley Berger filed Form 4 for Actinium Pharmaceuticals, Inc. (ATNM) on 03 Sep 2021.

Key facts

This page summarizes Mark Stanley Berger's Form 4 filing for Actinium Pharmaceuticals, Inc. (ATNM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Sep 2021, 17:04.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +67,164
Change %
Price: $0.000000
Shares after: 67,164
Date: 01 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,164
Exercise price: $6.07
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.

Footnote F2

Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested.